MCRB News and Press, Seres Therapeutics Inc. From 08/01/23

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a general business update. To access the con...

2023-07-10 13:47:02 ET Summary Seres Therapeutics and Nestlé Health Science received FDA approval for VOWST, a drug to prevent recurrent C. difficile infection, triggering a $125M payment from Nestlé to Seres. Seres reported a Q1 2023 net loss of $71.2M, up from a $56.6M...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 companies making an extraordinary impact around the world. Seres was included within the ‘ Pioneers’ cate...

– Post-hoc analysis results with VOWST highlight the importance of gut microbiome diversity as a critical component of a treatment regimen to reduce the risk of recurrent C. difficile infection in rCDI patients, regardless of the number of prior recurrences – Ser...

2023-06-07 11:16:58 ET Are you searching for some of the best penny stocks to buy now? I’m sure that if you’re reading this article, that’s something at the top of your mind. But there’s more to it than just hunting for today’s top movers. Are you day trad...

2023-06-05 14:59:12 ET Seres Therapeutics ( NASDAQ: MCRB ) and partner Nestle Health Science ( OTCPK:NSRGY ) announced the the US launch of their new treatment Vowst for the prevention of recurrence of C. difficile infection in adults who have already been treated with anti...

– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI – – VOWST Voyage™ Support Program to help reduce out-of-pocket patient costs for eligible patients and facilitate treatment start – ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ...

2023-05-30 16:26:43 ET Seres Therapeutics ( NASDAQ: MCRB ) said it received a $125M milestone payment from Nestlé Health Science following the FDA approval of Vowst for preventing recurrence of C. difficile Infection ( CDI ) in adults after antibiotic treatment for recurr...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores,...